Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MSD Seeks Capvaxive Use in High-Risk Children in Japan
MSD has moved to broaden the label of its 21-valent pneumococcal conjugate vaccine Capvaxive in Japan, seeking to extend its use to children who are considered at increased risk of pneumococcal disease. The company said on November 7 that it…
To read the full story
Related Article
- MSD Launches 21-Valent Pneumococcal Vaccine Capvaxive in Japan
October 30, 2025
BUSINESS
- J-Pharma Goes Public on TSE, Eyes Licensing of LAT1 Inhibitors
March 26, 2026
- Asahi Kasei Banks on Tarpeyo to Hit 300 Billion Yen in Pharma Sales by FY2030
March 26, 2026
- Takeda Unveils Annual 200 Billion Yen Cost Savings by FY2028
March 26, 2026
- SanBio Targets Akuugo Shipments after May NHI Listing
March 26, 2026
- Tracleer Generics Add Digital Ulcer Prevention Use
March 26, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…